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Abstract: The current treatment for cervico-facial cancer involves radio and/or chemotherapy.
Unfortunately, cancer therapies can lead to local and systemic complications such as mucositis,
which is the most common dose-dependent complication in the oral cavity and gastrointestinal
tract. Mucositis can cause a considerably reduced quality of life in cancer patients already suffering
from physical and psychological exhaustion. However, the role of melatonin in the treatment of
mucositis has recently been investigated, and offers an effective alternative therapy in the prevention
and/or management of radio and/or chemotherapy-induced mucositis. This review focuses on the
pathobiology and management of mucositis in order to improve the quality of cancer patients’ lives.
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1. Overview of Mucositis Pathobiology
Mucositis, one of the most severe toxic side effects of cancer therapy, can affect the entire
gastrointestinal tract, with the oral cavity being the most common affected site. It presents in virtually
all head and neck cancer patients receiving chemo and/or radiotherapy, in 60–85% of those receiving
myeloablative therapy for stem-cell transplantation, and in 20–40% of patients receiving conventional
chemotherapy [1–3]. The use of concomitant chemotherapy and/or targeted agents increases the risk
of mucositis.
Oral lesions lead to considerably decreased quality of life in these patients due to solid and
liquid food dysphagia, dysarthria, and odynophagia, resulting in depression in some patients, who
often require percutaneous endoscopic gastrostomy tube insertion [4]. In addition, mucositis lesions
may represent a gateway for opportunistic infections, can complicate cancer treatment, and extend
hospitalization [5,6]. On the other hand, given its dose-limiting toxicity for both chemo and radiotherapy,
mucositis can have a direct impact on survival rates [7].
2. Pathophysiology of Mucositis
Recent developments in mucositis research have highlighted multiple factors which contribute to
mucosal injury [8]. A five-phase chronological process has been proposed: initiation, primary damage
response (upregulation and message generation), signal amplification, ulceration, and the healing
phase [9]. Mucositis commences when gastrointestinal (GI) mucosa are exposed to cytotoxic agents,
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resulting in cellular DNA damage and cell death, mainly through the generation of oxidative stress
and reactive oxygen species (ROS) formation. ROS directly induce tissue injury and trigger a cascade
of inflammatory pathways [10]. Ortiz et al. have also observed a mitochondrial oxidation response to
radiation with subsequent mitochondrial dysfunction [11].
The progression of mucositis is characterized by significant inflammatory mediator up-regulation
due to the activation of the NF-κB pathway (upregulation and message generation phase). This is
followed by the signaling and amplification phase, during which, once activated by chemotherapy and
ROS, NF-κB promotes the expression of multiple pro-inflammatory molecules, including inducible
nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, and pro-IL-1β, and ensures feedback
amplification of the NF-κB-dependent signaling pathway [10]. Furthermore, mitochondrial ROS
production promotes inflammation by activating a multi-protein cytoplasmic complex, such as the
NLRP3 (NACHT, LRR, and PYD domains-containing protein 3) inflammasome. NLRP3 inflammasome
assembly leads to caspase-1 activation and subsequent cleavage of pro-cytokines such as pro-IL-1β,
pro-IL-18, and pro-IL-33 into their mature form [11,12] resulting in ulceration (ulceration phase).
Therefore, the NF-κB pathway, mitochondrial dysfunction, and subsequent NLRP3 inflammasome
activation are the three main players involved in the development of oral mucositis, which amplify the
whole inflammatory process via positive feedback loops, thus prolonging tissue injury and ending in
the healing phase.
During the initiation phase of mucositis, patients begin to develop erythema followed by focal
areas of oral mucosal desquamation [13], which mainly occur at the submucosa and basal epithelium
level. Therefore, although no evident damage to mucosal integrity is observed clinically, the tissue
biology is altered [10]. The progression of mucositis is then prolonged and severe, mucosal integrity is
breached, ulceration begins to form and the patient starts to have a burning sensation. Atrophic changes
occur in the GI mucosa, culminating in tissue injury and stem cell death. GI epithelial integrity and
function are destroyed and impaired, respectively. A fibrinous exudate, or pseudomembrane, containing
bacteria covers the ulcer. Bacterial colonization at the mucosa ulcers further induces inflammation
by stimulating infiltration and activation of macrophages, which occurs approximately two weeks
after therapy [10]. Cell wall residues originating from colonizing bacteria penetrate the submucosa,
where they activate macrophages in the infiltrate [14]. This can lead to prolonged hospitalization, the
need for parenteral nutrition, severe pain, risk of infection and sepsis, and increased risk of morbidity
and mortality.
The final stage of mucositis pathobiology is the healing process. Epithelial cells controlled by
signals secreted by the extracellular matrix, which are then downregulated to avoid hyperplasia,
migrate, grow, and differentiate to form a wound. With the healing process under way, symptoms begin
to abate [9], and healing is completed within 4 weeks after the final dose of radiation. Unfortunately,
even after full replenishment of the epithelium, the structure of the reconstituted submucosa differs
from its pre-radiotherapy state [15].
Intestinal mucositis is also a common side effect of anticancer chemotherapy that involves
the small intestines. In intestinal mucositis, histopathological changes are also associated with the
production of ROS and the amplification of inflammatory signals induced by anticancer drugs or
radiation. Keefe et al. [16] studied patients undergoing chemotherapy with sequential duodenal
biopsies pre and post treatment. They found that an increase in apoptosis was the first histological
effect to be noted, with a seven-fold increase in apoptosis in intestinal crypts at day one post treatment.
Reduction of the intestinal villous area, crypt length, and crypt proliferation then followed and
the maximal effect was observed 3 days post treatment. Research is ongoing to fully elucidate the
mechanisms of intestinal mucositis. The loss of crypt stem cells remains an important event in intestinal
injury following anticancer treatment. However, it is not the sole contributing factor leading to overt
damage. The inflammatory cascade is being realized as an important pathway in the development of
intestinal mucositis that can be pharmacologically manipulated [17].
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On the other hand, radiation-induced damage to healthy intestine tissue is a common side-effect
caused by out-of-field or scattered radiation [18]. We recently demonstrated that tongue irradiation
also induces intestinal damage. Typical macroscopic traces of mucositis were also detected in the small
intestines of irradiated animals, including a significant decrease in villus height and morphological
alterations associated with substantial intestinal architecture changes [19]. Given the involvement
of mitochondrial oxidative stress, bio-energetic impairment, and subsequent NLRP3 inflammasome
activation in the development of radiotherapy-induced gut toxicity, the oral irradiation of rats also
resulted in increased small intestinal damage.
3. Mucositis Management
As there is no effective therapy for mucositis or its associated pain, a large number of studies have
been conducted in this field. Strategies for managing oral mucositis include preventative measures
and therapeutic approaches (Figure 1) [13].
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doxepin appears to be effective for easing acute oral mucositis pain caused by radiation therapy 
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mouthwashes are effective [27]. Another type of topical agent is the transdermal patch, composed of 
fentanyl, which is a potent, fast, and short acting synthetic opioid analgesic, although transdermal 
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a potent, fast, and short acting synthetic opioid analgesic, although transdermal fentanyl causes mild
dizziness, gastrointestinal reactions, and itching [28].
Oral decontamination, involving treatments such as Nystatin and chlorhexidine [29], may result
in significant positive outcomes in the prevention of ulcerations linked to oral mucositis. Recently,
Silva et al. [30] tested a soft pastille formulation consisting of 0.25% lidocaine and 78,000 IU Nystatin,
which was found to facilitate accurate drug administration by physicians and to enable patients to
control drug retention time in the mouth in order to manage the pain treatment process. On the other
hand, chlorhexidine is an effective broad-spectrum antiplaque antiseptic agent [31]. However, these
drugs are not very effective in reducing the severity or incidence of mucositis [32,33].
Cryotherapy, during which patients suck on ice chips for 30 min prior to and during chemotherapy
infusion [34–37], has been shown to effectively attenuate the onset and severity of mucositis in patients
undergoing chemotherapy with 5-fluorouracil and melphalan. However, it is only effective for short
bolus chemotherapeutic infusions [38], may not be tolerated by some subjects, and thus cannot play
a significant role in radiation-induced oral mucositis treatments [25].
Several antioxidant agents to prevent mucositis or to reduce its severity have been tested. One of
the first drugs used to treat mucositis was amifostine [13], a thiol compound which is dephosphorylated
to an active metabolite and acts as a potent ROS scavenger. However, given its limited and inconsistent
results, amifostine is not recommended for the prevention of oral mucositis in patients receiving
either chemotherapy or radiotherapy alone [39]. N-acetyl cysteine (NAC) is another antioxidant
containing thiol groups, which stimulates glutathione synthesis and scavenges free radicals. In addition
to its antioxidant properties, NAC prevents NF-κB activation which increases the inflammatory
response. In a double-blind, randomized, placebo-controlled trial, NAC significantly reduced severe
oral mucositis incidence [40].
Given that a reduction in the proliferative capacity of oral epithelial cells is thought to play a role
in mucositis pathogenesis, various growth factors capable of increasing epithelial cell proliferation have
been studied with regard to oral mucositis management. Although palifermin, an epithelial-specific
growth factor, is the only agent approved for the prevention of oral mucositis in bone-marrow transplant
patients [41], it is also associated with adverse side effects, requires intravenous administration, and
is expensive [42]. Other growth factors, such as velafermin, filgrastim, and argramostim, have been
analyzed for use in the treatment of mucositis [43]. Smad7, which has recently received considerable
attention [44], was initially identified as a TGF-β superfamily signaling antagonist, which blocks
TGF-β-induced growth inhibition and apoptosis in keratinocytes [45] and reduces inflammation by
antagonizing NF-κB activation. All of these characteristics may make Smad7 beneficial in the treatment
of oral mucositis [44].
Several anti-inflammatory agents have produced good results in studies of oral mucositis in
animals; there is still conflicting evidence, however, on the efficacy of these agents in reducing the
severity of mucositis in humans [13]. Benzydamine HCl is a non-steroidal anti-inflammatory drug
that inhibits pro-inflammatory cytokines including TNF-α, and IL-1β. It has been administered in
an intravenous formulation recommended for the prevention of oral mucositis in patients with head
and neck cancer receiving moderate-dose radiation therapy without concomitant chemotherapy [46].
A long list of anti-inflammatory drugs has produced inconsistent results with regard to the prevention
of chemotherapy-induced oral mucositis. This is the case for Misoprostol, a synthetic prostaglandin
E1 analog, which has anti-inflammatory mucosa protection properties. However, the overall results
of using misoprostol mouthwash in the prevention of radiation-induced oral mucositis in head
and neck cancer patients were negative [47,48]. While glutamine, a nonessential amino acid, may
mitigate mucosal injury by reducing pro-inflammatory cytokine production and cytokine-related
apoptosis [49,50], it produced inconsistent results in the prevention of chemotherapy-induced oral
mucositis [51–53].
Multiple studies have indicated that the application of low-level laser therapy (LLLT) reduces
the incidence and, by hastening oral re-epithelialization, favorably influences oral mucositis
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outcomes in patients undergoing standard, hematopoietic stem cell transplantation and myeloablative
chemotherapy [54–59]. Although the mechanism involved in these benefits is not understood, it has
been suggested that LLLT may reduce ROS and/or pro-inflammatory cytokine levels which contribute
to mucositis pathogenesis [25]. However, many of the pathways stimulated by LLLT are associated
with undesirable tumor behaviors and/or treatment responses [60].
Moreover, there are some exciting approaches to the treatment and prevention of intestinal mucositis
that could potentially be extended to the oral mucosa. These include probiotics, probiotic-derived
factors, and plant extracts and preparations. A research study conducted by Yeung et al. [61] found
that the daily oral administration of a probiotic suspension of Lactobacillus casei variety rhamnosus
(Lcr35) or Lactobacillus acidophilus and Bifidobacterium bifidum (LaBi) resulted in the attenuation of
diarrhea, proinflammatory cytokines, and jejunal villi damages in 5-FU(fluorouracil) -induced intestinal
mucositis. Furthermore, a prospective open-labeled randomized trial in Sweden documented that
Lactobacillus rhamnosus administration twice daily for 24 weeks reduced grade 3 or 4 diarrhea in
patients and minimized the hospitalization due to bowel toxicity [62]. However, a major limitation
of the Osterlund et al. [62] study was the lack of blinding and placebo control. A large prospective,
double-blinded, placebo-controlled randomized trial at a single institution in Italy investigating the
role of probiotics in the prevention of RT-induced acute diarrhea was conducted by Delia et al. [63].
The patients received a VSL#3® sachet contained 4.5 × 1011/gram of viable lyophilized bacteria
including four strains of Lactobacilli, three strains of Bifidobacteria, and one strain of Streptococcus.
The authors found that significant improvements were noted in diarrhea. However, the overall
methodology and results are very sparse in detail, limiting the reader’s ability to follow the trial.
Finally, traditional Chinese Medicine (TCM) offers empirical herbal formulas for treating mouth
ulcers and stomatitis which has frequently been used in the complementary treatment of oral
mucositis, but the evidence for these therapies is unclear and in some cases they have not been
effective [64]. Also, the standard concepts for this kind of treatment do not exist and the acceptance by
conventional oncologists is still low. In western complementary medicine, several herbal treatment
approaches exist including Salvia officinalis, Matriciana camomilla, Calendula officinalis, Hamamelis
virginiana, Potentilla erecta, Commiphora molmol, Myrtilli fructus, Althaea spps, Malva spps, Cetraria
islandica, Linum usitatissimum, Flos caryophylli, Hippophae rhamnoides, Aloe vera, Carica papaya, Centaurii
herba, Gentianae radix, Menyanthes folium, Eriodictyon crassifolium, Oleum olivae and Citrus limon.
They are applied as single infusions for gargling or topical application [65]. Of these, Matriciana
camomilla, Salvia officinalis, Chimonanthus salicifolius, Aloe vera, Gentianae radix and date palm pollen
have been used [65–69]. The anti-mucositis activity of different herbs might be due to inhibiting
apoptosis and inflammation in GIT (gastrointestinal tract). However, later phase III trials of Matricaria
chamomilla have failed to conclude that the chamomile given in mouthwash formulations is effective in
patients with chemotherapy-induced mucositis [70]. Table 1 summarizes the different agents used in
mucositis management.
Table 1. Studies which evaluated the effect of different agents on the management of mucositis.
Agent Experiment Subject Outcomes Reference
Mouth rinse
Traumeel S
A randomized, controlled clinical trial of the
homeopathic medication Traumeel S in the
treatment of chemotherapy-induced stomatitis in
children undergoing stem cell transplantation
Human







placebo-controlled trial to assess the
efficacy of a mucoadhesive hydrogel (MuGard)
in mitigating oral mucositis symptoms in
patients being treated with chemoradiation
therapy for cancers of the head and neck
Human MuGard lessened the severity ofthe developing mucositis and pain [21]
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Table 1. Cont.
Agent Experiment Subject Outcomes Reference
Topical agents
Fentanyl
Efficacy and safety of transdermal fentanyl
for the treatment of oral mucositis pain
caused by chemoradiotherapy in patients
with esophageal squamous cell carcinoma
Human
Fentanyl was effective in treating





Efficacy of chlorhexidine and nystatin rinses
in the prevention of oral complications in
leukemia and bone marrow transplantation
Human
Nystatin rinse has not been found to







Review of preventive strategies and treatment
Human
Amifostine may reduce the frequency
of severe esophagitis in patients
undergoing concomitant
chemotherapy and radiotherapy




N-acetyl cysteine for the prevention of oral
mucositis in hematopoietic sct: A double-blind,
randomized, placebo-controlled trial
Human
NAC significantly reduced the
incidence of severe oral mucositis
(grades 3–4) after high-dose
chemotherapy and no patient in the





Prospective evaluation of a chamomile
mouthwash for the prevention of
5-FU-induced oral mucositis
Human
Later phase III trials of Matricaria
chamomilla have failed to conclude
that the chamomile given in








Palifermin for oral mucositis after
intensive therapy for hematologic cancers Human
KGF significantly reduced the
incidence of grade 3 and 4 oral








Recombinant human epidermal growth factor
treatment of radiation-induced severe oral
mucositis in patients with head and
neck malignancies
Human
rhEGF has been shown to enhance the
mucosal wound healing process and





Oral glutamine reduces the duration and severity
of stomatitis after cytotoxic cancer chemotherapy.
Oral glutamine to alleviate radiation-induced
oral mucositis: A pilot randomized trial
Human
In two small, randomized studies
prophylactic glutamine mouthwashes
significantly reduced the incidence,
severity, and duration of oral




Locally applied nonpharmacological agents
Low level laser
therapy (LLLT)
Cyclooxygenase-2 and vascular endothelial
growth factor expression in
5-fluorouracil-induced oral mucositis in
hamsters: evaluation of two
low-intensity laser protocols
Hamster
LLLT promotes wound healing and
appears to have an anti-inflammatory
effect, as evidenced by the reduction
in neutrophil infiltrate
[76]
Phase III trial of low-level laser therapy to
prevent oral mucositis in head and neck cancer
patients treated with concurrent chemoradiation
Human
Preventive LLLT in HNSCC (head
and neck squamous cell carcinoma)
patients receiving chemoradiotherapy
is an effective tool for reducing the
incidence of grade 3-4 oral mucositis
[77]
4. Melatonin: A New Treatment for Mucositis
Melatonin (N-acetyl-5-methoxytryptamine), a hormone synthesized from tryptophan, is produced
by the pineal gland; it has been detected in multiple extrapineal organ tissues at much higher
concentrations than in the pineal gland [78]. It is a potent free radical scavenger with anti-oxidant
properties (Table 2), which increases the expression and activity of endogenous antioxidant enzymes
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such as superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase
(GRd), and γ-glutamyl-cystein synthase. This special class of antioxidant generates a series of
metabolites that are also free radical scavengers when scavenging free radicals [79–83]. In other
words, as compared to other antioxidants, melatonin is more effective in preventing damage caused
by oxidative stress. Capable of crossing cell membranes and of easily reaching all cell compartments, it
is taken up by mitochondria and can maintain mitochondrial homeostasis in different experimental
models [78,84–87]. Melatonin increases membrane fluidity, electron transfer chain (ETC) complex
activity, ATP production, and mitochondrial membrane potential, while reducing oxidative stress and
closing mitochondrial permeability transition pores (MPTPs) [88]. Its important anti-inflammatory
effects include expression inhibition of iNOS/i-mtNOS, COX-2, and pro-inflammatory cytokines such
as IL-1β or TNF-α. Many of these properties are attributed to the inhibition of NF-κB-dependent
innate immune pathway activation [89,90], and we recently showed that melatonin blunts NLRP3
inflammasome activation under different experimental conditions [11,91,92]. Table 2 summarizes the
biological effects of melatonin.
4.1. Melatonin in the Oral Cavity
We recently demonstrated that melatonin is synthesized in oral mucosa, where it is involved
in autocrine/paracrine signaling by binding to MT1 (melatonin receptor type 1A), MT2 (melatonin
receptor 1B), and RORγ (RAR-related orphan receptor gamma) receptors, thus suggesting that it plays
a role in normal oral mucosal physiology [11]. We found that aralkylamine N-acetyltransferase (AANAT)
and acetylserotonin O-methyltransferase (ASMT), the two main enzymes in melatonin synthesis, are
expressed in oral mucosa and also in salivary glands. However, melatonin, which is also found in saliva,
is believed to passively enter the mucous through the circulatory system in salivary glands (parotid,
submaxillary, and sublingual glands) [78,93]. Thus, as the quantity of melatonin entering the oral cavity is
proportional to salivary flow, xerostomia, which actually aggravates periodontal status, could be associated
with oral pathologies [94]. Together, these data, which are corroborated by the literature, demonstrate
that melatonin has important implications for the prevention of oral cavity diseases by limiting tissue
damage through free radicals and by stimulating immune responses. Almughrabi et al. demonstrated
the relationship between low levels of melatonin in saliva and the increased severity of oral pathologies
such as gingivitis, chronic periodontitis, and aggressive periodontitis [95]. The beneficial effects of topical
melatonin applications in patients with periodontal diseases, as evidenced by improvements in the
gingival index and pocket depth, have been established by Gomez-Moreno et al. [96]. Melatonin has
also been proven to be an effective treatment for oral infections such as herpes [94]. Kara et al. showed
that it decreases proinflammatory cytokines in gingivitis and periodontitis [97]. Cutando et al. [98]
showed that melatonin treatment in patients with diabetes significantly reduced the gingival index,
pocket depth, and RANKL (receptor activator of nuclear factor kappa-B ligand) levels, and also increased
osteoprotegrin concentrations. Due to its anti-inflammatory and anti-oxidative effects, the severity of
gingival and periodontal inflammation was reduced. Other studies have demonstrated that melatonin
could be a beneficial therapy after surgical procedures in the oral cavity by preventing inflammatory and
infectious complications induced by oxidative stress [99]. Cutando et al. [99] showed that topically applied
melatonin in the evacuated sockets following tooth removal reduced oxidative stress and inflammation
and accelerated the healing process. Thus, by being directly deposited in the oral cavity, it has the
capacity to treat oral disorders and pathologies by reducing inflammatory responses in the gingiva
and periodontium [94].
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Table 2. Melatonin biological effects. Up arrows (increase) whereas, down arrow (decrease).
Molecule, Activity, or Process Biological Effect of Melatonin References
Reactive oxygen species
OH• − (hydroxyl radical) ↓ [100]
O2• − (oxygen free radical) ↓ [100]
H2O2 (hydrogen peroxide) ↓ [83]
LO• −, LOO• − (alkoxyl, peroxyl radicals) ↓ [101]
NO (nitric oxide) ↓ [83]





NF-κB (nuclear factor-κB) ↓ [11,91,92]
COX-2 (cyclooxygenase-2) ↓ [105]
Interleukins ↓ [106,107]
NLRP3 ↓ [11,91,92]
TNF- α (tumor necrosis factor-α) ↓ [106,107]
iNOS (inducible nitric oxide synthase) ↓ [106,107]
MPO (myeloperoxidase) ↓ [108]
Cell death
p53 ↓ [109]
Caspases (Cas-3, 8, 9, . . . ) ↓ [11,83]
cytochrome c (in cytosol) ↓ [109]
Bcl-2, Bcl-xL (anti-apoptosis) ↓ [11,83]
Bax, Bak (pro-apoptosis) ↓ [11,83]
Autophagy
Beclin-1, Atg3, Atg12, . . . . (pro-autophagy) ↓ [110,111]
mTOR (pro-autophagy) ↓ [110,111]
PI3K/Akt (anti-autophagy) ↑ [110,111]
Antioxidative defense system
GSH (glutathione) ↑ [11,83]
SOD (superoxide dismutase) ↑ [11,83]
CAT (catalase) ↑ [11,83]
GPx (glutathione peroxidase) ↑ [11,83]
GRd (glutathione reducatse) ↑ [11,83]
glutathione synthetase ↑ [112]
γ-glutamyl-cysteinyl synthetase ↑ [112]
4.2. Melatonin as a Radio-Protective Agent
For many years, the radio-protective effects of melatonin have been observed in different
experimental models as well as organs and tissues. Tan et al. [113] were the first to report its ability
to protect against electromagnetic radiation emitted by ultraviolet light, with subsequent studies
reporting its effectiveness in protecting against ionizing radiation. Vijayalaxmi et al., who carried out
a series of experiments to study the radio-protective effects of melatonin in vitro and in vivo, showed
that melatonin guarded against γ radiation-induced cell damage in blood lymphocytes [114–117].
Other authors have reported that it prevents hemolysis in irradiated human red blood cells [118].
Pretreatment with melatonin guards erythrocytes, granulocytes, macrophages, megakaryotes, and T
cells against radiation-induced cellular injury and also inhibits splenocyte apoptosis in whole-body
irradiated mice [119]. It also prevents radiation-induced damage in retinal cells [120], thymocytes [121],
and bone-marrow cells in mice [122]. Several in vivo studies reveal that it increases the survival rate
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of animals exposed to radiation. Pre-treatment with 250 mg/kg melatonin raised the survival rate
of lethally whole-body irradiated (9.5 Gy) mice [123] to approximately 43% and to 85% at a dose
of 8.15 Gy [124]. Iwata et al. demonstrated that pre-treatment with intraperitoneally administered
melatonin at a dosage of 150 mg/kg showed a survival rate of around 100% for mice following
a radiation dose of 7.5 Gy [125], with an amelioration in radiation-induced injury in radio-sensitive
organs such as bone marrow, spleen, and gastrointestine [126]. In all these experiments, melatonin
was observed to protect against radiation-induced genotoxicity in both the somatic and germ cells
of mice. Its radio-protective impact was also demonstrated in the testis and ovary of irradiated
rodents [127–130]. Melatonin also plays an important protective role against radiation-induced damage
to the thyroid gland [131] and the small intestine [132], which is one of the most radio-sensitive organs,
resulting in inflammation-induced radiation enteritis. Its administration prior to irradiation guards
against intestinal damage caused by X-rays [133]. It prevents mucosal intestinal damage caused by
radiotherapy by countering structural changes in the small intestine (as evidenced by the villous
pattern of the intestinal mucosa) [134] and also inhibits gut bacterial translocation to the spleen, liver,
and kidney [119].
The mechanisms involved in melatonin as a radioprotective agent have been attributed to its
antioxidant properties, which reduce radiation-induced DNA damage and lipid peroxidation, and
to its protection of the immune system by reducing apoptosis through the inhibition of p53 and Bax
and by enhancing anti-apoptotic protein Bcl-2 [119,126,135]; it is also involved in repairing lesions in
cellular DNA [136].
In patients, the administration of melatonin resulted in amelioration of hypotension, myelotoxicity,
and lymphocytopenia associated with radiotherapy [137]. Therefore, its use as a prophylactic agent could
reduce morbidity and limit radiation-induced injury in cancer patients under radiotherapy [119,135].
4.3. The Use of Melatonin in the Prevention of Radiation-Induced Mucositis
Together, given the data summarized in this review, highlighting its anti-inflammatory and
antioxidant function in the oral cavity and its potential effectiveness in protecting against ionizing
radiation, melatonin could, in our view, play a beneficial role in the prevention of mucositis.
We demonstrated that the application of a melatonin gel to oral mucosa prevented oral mucositis
in irradiated rats [11]. For these experiments, the tongue was irradiated under anesthesia (1 mL
equithesin/kg body weight, IP) at 7.5 Gy/day for 5 consecutive days. Melatonin gel or vehicle was
applied in the oral cavity 48 h before each irradiation dose and up to 14 days after the last irradiation
exposure. Melatonin gel was applied three times a day in the intraoral regions using a plastic Pasteur
pipette. The gel containing 3% melatonin was dissolved in 0.3% ethanol:Pluronic F-127. The gel was
made in our laboratory and it is under patent. Previously, we performed a dose-response study and the
maximal therapeutic effect was obtained with 3% melatonin gel. Therefore, in the group that received
melatonin gel, the total melatonin dose was 45 mg/day for 21 days. The purpose of this study was to
investigate the pathophysiology of oral mucositis and how melatonin can prevent its development.
We observed that melatonin gel is capable of preventing mucosal disruption and the emergence of
ulcers. Furthermore, it can prevent the loss of proliferative progenitor stem cells caused by radiation and
enhance their capacity to repopulate the tissue. In addition, ionizing radiation exposure causes oxidative
damage to DNA, which arrests the cell cycle, inhibits growth, and increases cell death [119]. Thus, the
protection of cellular DNA is of utmost importance in reducing radiation-induced cellular perturbation
and also in the proliferation/differentiation of normal cells. Melatonin treatment significantly reduces
radiation-induced DNA degradation. Therefore, given the high dependence of both epidermis and
mucosal epithelia on resident self-renewing stem cells, the therapeutic interventions using melatonin
described above, which can reduce the deleterious effects of radiation on normal epithelial stem cells,
could have a considerable impact on the quality of life of cancer patients.
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On the other hand, it is well known that irradiation inhibits the activity of mitochondrial ETC
complexes which enhances electron leakage and subsequent superoxide anion (O2• −) generation,
leading to persistent oxidative stress, responsible, at least partially, for radiation-induced cell death in
normal human fibroblast cells [138]. Given the induction of mitochondrial dysfunction by ionizing
radiation, we assessed whether mitochondrial damage is involved in radiation-induced mucositis.
We also determined whether the known improvement by melatonin of mitochondrial function could
protect oral mucosa against deleterious radiation effects. In our experiments, we found that the
application of melatonin gel decreased the radiation-induced oxidation responses of mitochondria.
We also observed that the protective effect of melatonin was mediated by the increased expression
and activity of mitochondrial antioxidant enzymes such as GRd. This reduced the mitochondrial
GSSG/GSH (oxidized glutathione/reduced glutathione) ratio and restored mitochondrial GSH
homeostasis [84], thus enabling mitochondria to recover from post-radiation oxidative stress. This is in
line with the finding that melatonin gel increases ETC protein expression and activity and also expands
citrate synthase activity, reflecting the increase in mitochondrial mass, resulting in a full recovery of
their bio-energetic capacity and the prevention of cell death. These findings suggest that the reduction
in mitochondrial damage by melatonin by preserving mitochondrial structure and function may
underlie its efficacy in preventing mucositis. The prevention of mitochondrial damage in irradiated
oral mucosa may therefore constitute one of the mechanisms by which melatonin protects against cell
death. Interestingly, we found that it inhibits mitochondrial-dependent apoptosis by decreasing the
Bax/Bcl-2 ratio. It also significantly inhibits p53 and Bax protein expression, while anti-apoptotic Bcl-2
protein expression increases considerably. Consequently, at least part of its radio-protective capacity
could depend on the inhibitory action of p53-related signaling proteins, which prevents the opening of
MPTPs and thus blocks the release of cytochrome c to the cytosol. In this regard, radiation induces
MPTPs to open up and mitochondrial DNA (mtDNA) to translocate to the cytosol. In addition to
ROS released from damaged mitochondria to the cytosol, mtDNA promotes the assembly of NLRP3
inflammasome, a multiprotein complex which activates caspase-1 [139]. Once activated, caspase-1
converts NF-κB-dependent pro-inflammatory cytokines, including pro-IL-1β, into a mature form.
Thus, the activation of both NLRP3 inflammasome and NF-κB innate immunity pathways leads to the
overproduction of IL-1β, TNF-α, and other pro-inflammatory mediators [139]. This double-stranded,
innate immune response by the NF-κB and NLRP3 inflammasome pathways could explain the difficulty
of finding an effective anti-mucositis therapy. Furthermore, the presence of impaired mitochondria
underlying these inflammatory responses makes the search for a specific treatment more difficult.
Our results highlight the importance of scavenging ROS and the protection of mitochondria from
irradiation in order to suppress inflammasome activation and consequently the development of oral
mucositis. This would, in turn, help to explain the therapeutic benefits of melatonin gel in combating
oral mucositis (Figure 2).
On the other hand, as discussed above, epithelial crypts in the intestinal region contain the highest
proliferating cells [140], which are extremely sensitive to ionizing radiation [141]. Recent studies
have reported that, even when the intestine is outside the irradiation field, radiation-induced damage
to healthy intestine tissue is a common side-effect of out-of-field or scattered radiation. This could
explain why typical signs of mucositis were detected in the small intestine following tongue irradiation.
Histological analysis revealed crypt loss, lower villi numbers, and shorter lengths in the gastrointestinal
region, leading to the conclusion that radiation enteropathy prevention requires protection of the
small intestine. Melatonin gel treatment in the mouth, which was observed to reduce intestinal
morpho-pathological changes [19], is therefore also associated with improved preservation of both
small intestinal and oral mucosa.
In addition, a number of studies have shown that melatonin contains remarkable oncostatic
properties. Its antiproliferative properties have been demonstrated in an extensive variety of tumors,
including breast, endometrial, prostate, colon, and ovarian cancers as well as choriocarcinoma,
melanoma, neuroblastoma, and osteosarcoma among others [142,143]. Its oncostatic mechanisms
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are associated with several hallmarks of cancer. Its anticancer action directly inhibits the proliferation
and growth of tumor cells [144]. Melatonin protects normal cells from apoptosis, while, at the same
time, promoting apoptotic cell death in several types of cancer cells [145]. Its immune-modulatory
anticancer action also augments antitumor immune response [146]. Additionally, melatonin has
an important metabolic effect, which decreases glucose uptake by cancer cells [147] and inhibits tumor
growth through the suppression of the uptake of linoleic acid and its metabolism by the tumor to the
mitogenic molecule 13-HODE [148]. Its anti-angiogenic and anti-metastatic properties have also been
reported in numerous studies [149–151]. Given its capacity to increase the efficacy of anticancer drugs,
these data show that melatonin can be used not only to treat mucositis due to the absence of adverse
side effects, but also can be used in cancer co-treatment programs.
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5. Conclusions
In summary, oral mucositis is a clinically important, deleterious consequence of chemo and
radiotherapy, for which no effective treatment has been found to date. Mucositis lesions can be painful,
affect nutrition and quality of life, and have significant economic impact. The p thogenesis of oral
mucositis is multifactori l and complex, and not ll mucositis can be prevented. Once mucositis has
eveloped, therapy should focus on supportiv care, which aims to maintain hydration, provide
appropriate caloric intake through e teral or parenteral nutritional suppor , relieve pain, and
prevent infection. This review discusses current cli ical practices in the management of or l mucositis
and emphasizes that no standard ther p utic approach has been developed for patients suffering
from oral mucositis. Thus, basic, translational, and clinical research into how to prevent and treat oral
and gastrointestinal mucositis continues. Our findings, showing that melatonin reduces irradiation
toxicity and prevents treatment-induced mucositis, indicate that, with its oncostatic and cytoprotective
properties, it constitutes an innovative, adjuvant strategy in the treatment of cancer. We demonstrated
that treatment with melatonin gel protects rats from post-radiation oral mucositis, prevents duodenal
inflammation and necrosis, and restores mucosal endogenous melatonin levels in irradiated animals.
A clinical trial of this gel, which is under patent, is currently underway to test for the prevention of
oral mucositis in head and neck cancer patients.
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CTCAE Common terminology criteria for adverse events
EGF Epidermal growth factor
G-CSF Granulocyte colony-stimulating factor
GIT Gastrointestinal tract
GM-CSF Granulocyte-macrophage colony stimulating factor
IL-1 Interleukin-1
MAPK Mitogen-activated protein kinase
MMP Matrix metalloproteinase
mTOR Mammalian target of rapamycin
NAC N-acetyl cysteine
NCI National Cancer Institute
NF-κB Nuclear factor-κB
NLRP3 NACHT, LRR, and PYD domains-containing protein 3




rhEGF Recombinant human EGF
ROS Reactive oxygen species
SAP Serum amyloid-P
Smad7 Mothers against decapentaplegic homolog 7
TCM Traditional Chinese medicine
TGF-β Transforming growth factor-β
TNF-α Tumor necrosis factor-α
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